Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
151results about "Nuclear receptor" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Bispecific antibodies
ActiveUS7235641B2Improve productivityImprove efficiencyAntipyreticAntibody mimetics/scaffoldsBispecific antibodyImmune effector cell
Owner:AMGEN RES (MUNICH) GMBH
Ecdysone receptor-based inducible gene expression system
This invention relates to the field of biotechnology or genetic engineering. Specifically, this invention relates to the field of gene expression. More specifically, this invention relates to a novel inducible gene expression system and methods of modulating gene expression in a host cell for applications such as gene therapy, large-scale production of proteins and antibodies, cell-based high throughput screetng assays, functional genomics and regulation of traits in transgenic plants and animals.
Owner:PRECIGEN INC
Novel substitution mutant receptors and their use in an nuclear receptor-based inducible gene expression system
This invention relates to the field of biotechnology or genetic engineering. Specifically, this invention relates to the field of gene expression. More specifically, this invention relates to novel substitution mutant receptors and their use in a Group H nuclear receptor-based inducible gene expression system and methods of modulating the expression of a gene in a host cell for applications such as gene therapy, large scale production of proteins and antibodies, cell-based high throughput screening assays, functional genomics and regulation of traits in transgenic organisms.
Owner:PRECIGEN INC
Bispecific antibodies
ActiveUS20050136050A1Less complexReduce in quantityAntipyreticAntibody mimetics/scaffoldsBispecific antibodyImmune effector cell
The present invention discloses bispecific antibodies comprising two antibody variable domains on a single polypeptide chain, wherein a first portion of the bispecific antibody is capable of recruiting the activity of a human immune effector cell by specifically binding to an effector antigen on the human immune effector cell, the first portion consisting of one antibody variable domain, and a second portion of the bispecific antibody specifically binding to a target antigen other than the effector antigen, the target antigen on a target cell other than the human immune effector cell, the second portion comprising one antibody variable domain.
Owner:AMGEN RES (MUNICH) GMBH
Chimeric retinoid x receptors and their use in a novel ecdysone receptor-based inducible gene expression system
InactiveUS20080263687A1FungiFusion with DNA-binding domainHigh-Throughput Screening AssaysBiotechnology
This invention relates to the field of biotechnology or genetic engineering. Specifically, this invention relates to the field of gene expression. More specifically, this invention relates to a novel ecdysone receptor / chimeric retinoid X receptor-based inducible gene expression system and methods of modulating gene expression in a host cell for applications such as gene therapy, large-scale production of proteins and antibodies, cell-based high throughput screening assays, functional genomics and regulation of traits in transgenic organisms.
Owner:RHEOGENE INC DE
Novel ecdysone receptor/invertebrate retinoid X receptor-based inducible gene expression system
This invention relates to the field of biotechnology or genetic engineering. Specifically, this invention relates to the field of gene expression. More specifically, this invention relates to a novel ecdysone receptor / invertebrate retinoid X receptor-based inducible gene expression system and methods of modulating gene expression in a host cell for applications such as gene therapy, large-scale production of proteins and antibodies, cell-based high throughput screening assays, functional genomics and regulation of traits in transgenic organisms.
Owner:PRECIGEN INC
Novel substitution mutant receptors and their use in a nuclear receptor-based inducible gene expression system
Owner:RHEOGENE INC DE
Peptide antiestrogen compositions and methods for treating breast cancer
InactiveUS6306832B1Low backgroundReduction of nonspecific backgroundPeptide/protein ingredientsGenetic material ingredientsCo activatorCancer research
Disclosed are methods and compositions comprising native, site-specifically mutagenized, and synthetic peptides comprising portions of the human estrogen receptor, or estrogen receptor co-activator, and nucleic acid compositions encoding these polypeptide compositions. Also disclosed are methods for synthesizing phosphotyrosyl and malonyltyrosyl peptide derivatives and their use as antiestrogen compositions in the treatment of breast cancers, the preparation of pharmaceutical compositions, diagnostic kits, and the development of related assays for use in antitumor therapies.
Owner:UNIVERSTIY OF CALIFORNIA
Method for producing immortalised antibodies-secreting cells
A method for producing immortalized antibody-secreting cells, comprising: (a) providing a transgenic animal having antibody-secreting cells capable of expressing one or more transgenes, wherein the antibody-secreting cells are in a non-immortalized state in the absence of a stimulus and are capable of changing to an immortalized state by means of the transgenes or transgenes upon exposure of the cells to the stimulus; (b) extracting the antibody-secreting cells from the animal; and (c) exposing the antibody-secreting cells to the stimulus, thereby immortalizing the antibody secreting cells by means of the transgene or transgenes.
Owner:GRANTA BIOTECH
Inducible expression systems employing PPAR transcriptional activators
InactiveUS20040038249A1Increase specificity and safetyReduce riskVectorsSugar derivativesSide effectTranscription control
The invention relates to novel mammalian perixosome proliferator-activated receptor (PPAR) poplypeptides and their use. In a particular embodiment, PPAR polypeptides with mutations in the P-box domain possess advantageous properties as transcriptional activators for PPRE-bearing expression vectors and expression systems. The invention includes PPAR polypeptides, nucleic acids encoding them, expression systems, vectors, and methods for inducibly expressing a gene of interest. The methods and expression systems of the invetion provide improved dose-response or inducibility characteristics, improved and / or altered effects on cellular PPAR function, and / or improved transcriptional control. The selection of a homologous PPAR polypeptide to prepare the novel PPAR polypeptide of the invetion for a cell or tissue also improves the immune reaction side effect potential for particular uses.
Owner:GENCELL SA
Novel substitution mutant receptors and their use in an ecdysone receptor-based inducible gene expression system
This invention relates to the field of biotechnology or genetic engineering. Specifically, this invention relates to the field of gene expression. More specifically, this invention relates to novel substitution mutant receptors and their use in a nuclear receptor-based inducible gene expression system and methods of modulating the expression of a gene in a host cell for applications such as gene therapy, large scale production of proteins and antibodies, cell-based high throughput screening assays, functional genomics and regulation of traits in transgenic organisms.
Owner:PRECIGEN INC
Estrogen-receptor based ligand system for regulating protein stability
Disclosed herein are systems, methods and compositions for rapidly and reversibly destabilizing a target protein in vitro or in vivo, in the presence or absence of a cell-permeable, synthetic molecule or ligand.
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV
Identification of novel pathways, genes and promoter motifs regulating adipogenesis
InactiveUS7759318B1Modulate level of expressionSugar derivativesGenetic material ingredientsDiseaseDiabetes mellitus
The present invention provides compounds, compositions, and methods for identification of motifs within regulatory regions of genes involved in adipogenesis and adipocyte differentiation. Compounds and compositions are provided for modulating expression of nuclear receptor / transcription factor-regulated genes. Methods for modulating the function of PPAR-γ as well as PPAR-γ-regulated gene promoters, and methods of using oligomeric compounds for diagnosis and treatment of diseases such as obesity and diabetes are also provided.
Owner:IONIS PHARMA INC
Treatment of osteolytic disorders and cancer using CSF1R extracellular domain fusion molecules
ActiveUS8183207B2Improve propertiesGrowth inhibitionPeptide/protein ingredientsAntibody mimetics/scaffoldsColony-stimulating factorColony Stimulating Factor Receptor
Owner:FIVE PRIME THERAPEUTICS
Method For Activating Efferent Sympathetic Nerves Innervating Adipose Tissues To Improve Obesity And Symptoms Associated Therewith
ActiveUS20080293830A1Function increaseDiminishingCompound screeningBiocidePeroxisomeSympathetic nerve
A method for activating an efferent sympathetic nerve innervating an adipose tissue and improving obesity-associated symptoms is provided, comprising stimulating an afferent vagal nerve from the liver without directly enhancing peroxisome proliferator-activated receptor (PPAR)-γ2 function in the liver.
Owner:TOHOKU UNIV
Steroidal ligands and their use in gene switch modulation
Owner:PRECIGEN INC
Ligand activated transcriptional regulator proteins
InactiveUS7329728B1Avoid undesirable immunological responseFungiPeptide/protein ingredientsNucleotideBinding domain
Fusion proteins for use as ligand-dependent transcriptional regulators are provided. The fusion proteins include a nucleotide binding domain operatively linked to a ligand-binding domain. They also can include a transcription regulating domain. The nucleotide binding domain is a zinc-finger peptide that binds to a targeted contiguous nucleotide sequence of from 3 to about 18 nucleotides are provided. The fusion proteins are used for gene therapy. Also provided are polynucleotides encoding the fusion proteins, expression vectors, and transfected cells.
Owner:THE SCRIPPS RES INST +1
Therapeutic effects of nurr1 and foxa2 in inflammatory neurologic disorders by m1-to-m2 polarization of glial cells
ActiveUS20170354688A1Reduce inflammatory factorIncrease neurotrophic factorPeptide/protein ingredientsGenetically modified cellsDiseaseNervous system
A therapeutic effect of Nurr1 and Foxa2 in inflammatory neurologic disorders by M1-to-M2 polarization of glial cells is provided. Specifically, a method of converting glial cells from an M1 phenotype to an M2 phenotype, wherein Nurr1 and Foxa2 are introduced into the glial cells to be overexpressed in the glial cells and a method of preventing or treating an inflammatory neurologic disorder, which includes glial cells into which Nurr1 and Foxa2 are introduced, or a viral vector loaded with Nurr1 and Foxa2, are provided.
Owner:INNOPEUTICS CORP
Gene expression modulation system for use in plants and method for modulating gene expression in plants
InactiveUS8115059B1Efficient use ofSugar derivativesOther foreign material introduction processesHost plantsExpression cassette
An EcR-based gene expression modulation system for use in plants includes an EcR gene expression cassette, a modified RXR gene expression cassette, and a gene-of-interest expression cassette, which can be expressed in a host plant cell.
Owner:UNIV OF KENTUCKY RES FOUND
Compositions and methods of modulating cholesterol metabolism
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST
Targeting of Notch3 receptor function for cancer therapy
The present invention involves the use of peptides from Notch3, and antibodies that recognize epitopes represented by those peptides, as anti-cancer agents. Methods of combination therapy using standard anti-cancer protocols in conjunction with Notch3 peptides and antibodies also are provided.
Owner:VANDERBILT UNIV
Ketone ligands for modulating the expression of exogenous genes via an ecdysone receptor complex
This invention relates to a method to modulate exogenous gene expression in which an ecdysone receptor complex comprising: a DNA binding domain; a ligand binding domain; a transactivation domain; and a ligand is contacted with a DNA construct comprising: the exogenous gene and a response element; wherein the exogenous gene is under the control of the response element and binding of the DNA binding domain to the response element in the presence of the ligand results in activation or suppression of the gene. The ligands comprise a class of ketones.
Owner:PRECIGEN INC
Targeting of notch3 receptor function for cancer therapy
The present invention involves the use of peptides from Notch3, and antibodies that recognize epitopes represented by those peptides, as anti-cancer agents. Methods of combination therapy using standard anti-cancer protocols in conjunction with Notch3 peptides and antibodies also are provided.
Owner:VANDERBILT UNIV
Method for activating efferent sympathetic nerves innervating adipose tissues to improve obesity and symptoms associated therewith
Owner:TOHOKU UNIV
Tyrosine kinase inhibitor compositions and methods for manufacturing and using them in the treatment of disease
Owner:LIGACEPT
Bacterial ligand-binding sensor
InactiveUS20060211046A1BacteriaFusion with post-translational modification motifInteinEstrogen receptor
The invention relates to fusion proteins and bacteria encoding them. The fusion proteins include a ligand-binding domain interposed between the splicing domains of an intein. An auxotroph-relieving protein domain is fused to one of the splicing domains so that the auxotroph-relieving function of the domain is activated upon ligand binding. The fusion proteins can be expressed in bacterial cells and used as sensors of binding of compounds with the ligand-binding domain of proteins such as the human estrogen receptors or the human thyroid hormone receptor. The bacterially expressed fusion proteins can detect and report agonist and antagonist activity characteristic of the naturally-occurring hormone with the ability to modulate the function of the protein from which the ligand-binding domain of the fusion protein is derived.
Owner:THE TRUSTEES FOR PRINCETON UNIV
Compound I and compound II as well as preparation methods and application thereof
ActiveCN105315281AHas the effect of immune adjuvantImprove anti-tumor effectOrganic active ingredientsImmunoglobulin superfamilyMelanomaChemical compound
The invention relates to a compound I and a compound II as well as preparation methods and application thereof. The newly synthesized compound shown in the formula I can stimulate anti-tumor congenital immunity and cellular immunity while greatly improving the anti-tumor effect of ethacrynic acid (EA) and drug design of anti-tumor immunity synergetic integration is explored; the anti-melanoma immune response mechanism of the compound shown in the formula I is proved; the compound shown in the formula II and prepared through covalence of the compound shown in the formula I and ROR1 obviously reduces growth of breast cancer subcutaneously transplanted tumors, the breast cancer treatment immune response mechanism of the compound shown in the formula II is proved, and meanwhile, the fact that the compound shown in the formula I not only has the functions of stimulating congenital immunity and adaptive immunity, but also has the effect of immune adjuvant is proved.
Owner:SHENZHEN UNIV +1
Methods and compositions of predicting activity of retinoid x receptor modulator
ActiveUS20150368720A1Chemical property predictionCompound screeningGenomic BiomarkerGenetic linkage disequilibrium
The present invention describes genomic biomarkers that have been discovered to correlate with varied individual responses (efficacy, adverse effect, and other end points) to therapeutic retinoid X receptor modulator, such as bexarotene, in treating diseases such as, non small cell lung cancer. The newly discovered biomarkers and others in linkage disequilibrium with them can be used in companion diagnostic tests which can help to predict drug responses and apply drugs only to those who will be benefited, or exclude those who might have adverse effects, by the treatment.
Owner:DENOVO BIOPHARMA HANGZHOU LTD
An endocrine disruptor high-throughput screening model and a screening method
ActiveCN109815532AQualitative Judgment ActivityGood forecastChemical property predictionMolecular designPerturbateurs endocriniensHigh-Throughput Screening Methods
The invention discloses an endocrine disrupter high-throughput screening model and screening method, and relates to the field of virtual screening and activity prediction of endocrine disrupters. Themethod comprises the following steps: extracting a first-stage warning structure, a second-stage warning structure and a third-stage warning structure of a compound aiming at a nuclear receptor, forming a nuclear receptor high-throughput screening model by the first-stage warning structure, the second-stage warning structure and the third-stage warning structure; carrying out graded warning structure matching on the target compound through a nuclear receptor high-throughput screening model, and carrying out ligand-ligand matching; Analyzing a receptor binding mode; and semi-quantitatively predicting the binding activity and the interference activity. The method overcomes the defect that the potential nuclear receptor-mediated endocrine disrupter cannot be effectively screened in a high throughput manner in the prior art, can be used for screening the potential nuclear receptor-mediated endocrine disrupter in a high throughput manner, and can be used for judging the receptor competitionactivity and the quasi-antibody activity of the nuclear receptor-mediated endocrine disrupter.
Owner:NANJING UNIV
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com